Show Summary Details
Page of

Antibodies: The therapeutic future 

Antibodies: The therapeutic future
Antibodies: The therapeutic future

Anthony Rees

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2022. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 21 May 2022

In this short ‘prospective’ the author suggest directions, currently poorly targeted by the academic and commercial research and development communities, that antibody-related therapies may take in the future. Many current therapeutic antibody developments are targeted at cancer but the escapology abilities of many tumours often block truly effective therapy. When considering antibody therapy for brain tumours, the blockading blood-brain barrier creates an access problem not yet really resolved. Again, the treatment of pregnant mothers with therapeutic antibodies can offer major advantages for the mother but in some instances passively transfer disadvantageous toxicities for the foetus. In all three of these areas there is reason to take a step back and re-evaluate the cost-benefit of current therapies and how they might be improved.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.